Step 1 topics → Biochemistry → Glycolysis Regulation (PFK-1 and Friends)

Glycolysis Regulation (PFK-1 and Friends)

USMLE Step 1 trap: Confuses ATP's role as a PFK-1 substrate with its allosteric inhibitory effect on PFK-1. High ATP allosterically inhibits PFK-1, signaling that energy is sufficient and glycolysis should slow down.

Glycolysis regulation centers on PFK-1 — the committed step and rate-limiting enzyme of the pathway. USMLE Step 1 hammers this topic because it sits at the intersection of energy sensing, hormonal signaling, and metabolic crosstalk. Students consistently invert how glucagon controls F2,6BP — they get the kinase/phosphatase domains of the bifunctional enzyme backwards — and many don't realize ATP both activates PFK-1 as a substrate and inhibits it allosterically at a different site. You need to know not just what regulates PFK-1, but why each signal makes physiological sense. The exam will give you a clinical or biochemical scenario (fed vs. fasted state, insulin vs. glucagon dominance, high vs. low energy charge) and ask you to predict what happens to glycolytic flux — that's application, not memorization.

The tricky part is that PFK-1 has multiple regulatory inputs from completely different signal axes, and the exam loves to test whether you understand what each signal actually means. ATP is a substrate AND an allosteric inhibitor — that dual role trips up almost everyone. Citrate inhibition gets lumped in with ATP/AMP by students who haven't thought about why the signal exists. And the F2,6BP story involves a bifunctional enzyme whose two activities are reciprocally controlled by glucagon vs. insulin — reversing those is one of the most common errors on this topic.

For USMLE Step 1, expect questions that embed the regulation in a hormonal or fed/fasted context, often in a passage with lab values or a metabolic scenario. The question isn't 'what inhibits PFK-1?' — it's 'a patient is in a fasted state with high glucagon; what happens to F2,6BP and glycolytic flux?' Build a mental model that connects each regulator to its physiological meaning, not just a list of activators and inhibitors.

From real student decks
43%have cards covering this topic
19%have mature cards

Common misconceptions

Common mistake
Wrong: High ATP activates PFK-1 because ATP is a substrate of the reaction.
Right: High ATP allosterically inhibits PFK-1, signaling that energy is sufficient and glycolysis should slow down.
ATP binds PFK-1 at two sites: the active site as a substrate, and a separate allosteric site as an inhibitor. When ATP is abundant, the allosteric inhibitory site dominates — this is the cell signaling that energy is sufficient and glycolysis doesn't need to run hard. Don't let substrate status override your thinking about allosteric regulation; the two are completely independent mechanisms happening at different sites on the enzyme.
Common mistake
Wrong: Hexokinase is the rate-limiting enzyme of glycolysis because it is inhibited by its product G6P.
Right: PFK-1 is the rate-limiting enzyme of glycolysis; hexokinase's product inhibition by G6P is a separate regulatory mechanism that does not make it rate-limiting.
Hexokinase is regulated by product inhibition (G6P feeds back to inhibit it), but that's a local feedback loop — it doesn't make hexokinase the rate-limiting step of the entire pathway. PFK-1 is the rate-limiting enzyme because it catalyzes the first irreversible, committed step that is unique to glycolysis (unlike hexokinase, whose product G6P feeds into multiple pathways). Rate-limiting means it sets the pace of the whole pathway; product inhibition just means it self-regulates.
Common mistake
Wrong: Citrate inhibits PFK-1 as part of the energy-charge signal alongside ATP and AMP.
Right: Citrate inhibits PFK-1 as a downstream substrate-availability signal (TCA backup), which is mechanistically distinct from the energy-charge signals of ATP and AMP.
ATP and AMP signal energy charge — how much ATP is available relative to AMP. Citrate is a completely different kind of signal: it's a TCA cycle intermediate that backs up into the cytoplasm when the TCA cycle is already saturated. High citrate tells PFK-1 'don't send more acetyl-CoA precursors downstream because the TCA is backed up' — it's a substrate-availability signal, not an energy signal. Grouping citrate with ATP/AMP on exams will cause you to misinterpret scenarios involving TCA flux vs. energy charge.
Common mistake
Wrong: Glucagon increases F2,6BP levels to stimulate glycolysis.
Right: Glucagon activates the phosphatase domain of the PFK-2/FBPase-2 bifunctional enzyme, lowering F2,6BP and inhibiting PFK-1; insulin does the opposite.
Glucagon raises cAMP → activates PKA → phosphorylates the bifunctional enzyme → shifts it toward FBPase-2 activity → F2,6BP goes DOWN → PFK-1 is less active → glycolysis slows. Insulin does the exact opposite: it dephosphorylates the bifunctional enzyme, favoring PFK-2 kinase activity, raising F2,6BP, and stimulating glycolysis. The mnemonic: glucagon = fasting = need glucose OUT of glycolysis, so it lowers the activator F2,6BP. Never flip this.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know all the allosteric regulators of PFK-1: what activates it (AMP, F2,6BP, fructose-6-phosphate) and what inhibits it (ATP, citrate, H+), and be able to apply this in a given metabolic state.
  2. Understand the bifunctional PFK-2/FBPase-2 enzyme: how glucagon (via PKA-mediated phosphorylation) activates its phosphatase domain to degrade F2,6BP, while insulin activates its kinase domain to produce F2,6BP — and trace the downstream effect on PFK-1 and glycolysis.
  3. Distinguish between the three distinct regulatory axes converging on PFK-1: the energy-charge axis (AMP activates, ATP inhibits), the TCA substrate-backup axis (citrate inhibits when TCA is already full), and the hormonal axis (insulin/glucagon control F2,6BP levels through the bifunctional enzyme).

Can you avoid these mistakes?

A cell has high AMP and low ATP. Predict the effect on PFK-1 activity and explain the physiological rationale — why does this make sense for the cell?
Glucagon is released during fasting. Trace the complete signaling pathway from glucagon receptor activation to the final effect on PFK-1 activity, naming every intermediate step including the bifunctional enzyme's domain activity and F2,6BP levels.
A researcher finds that blocking citrate transport out of the mitochondria prevents citrate-mediated inhibition of PFK-1. What does this tell you about the physiological signal that citrate represents, and how is this mechanistically different from ATP's inhibition of PFK-1?
A patient has a tumor that constitutively activates PFK-2 kinase activity regardless of hormonal input. Predict the effect on F2,6BP levels, PFK-1 activity, and glycolytic flux — and name which clinical phenomenon this resembles.

Related topics

Glycolysis (Pathway and ATP Yield) Nucleotide and Nucleic Acid Structure DNA Replication DNA Repair Pathways Mutations and Their Consequences

See how your Anki deck covers this topic.

Upload your deck for a free audit →